Imagine your skin covered in thick, itchy, scaly patches that don't go away. That's the reality for people with moderate to severe plaque psoriasis. A new drug, bimekizumab, was recently tested in a large group of 435 adults to see if it could help clear their skin better than a placebo. The study, which ran for about 10 months, specifically looked at how many people achieved a 90% improvement in their psoriasis area and severity score after 16 weeks. The company behind the drug, UCB Biopharma, sponsored this Phase 3 trial, which is a critical step before a treatment can be considered for approval. It's important to know that the detailed results—exactly how well it worked, how many people it helped, and what side effects occurred—haven't been made public yet. So, while this represents a significant step in research, we're still waiting to see the full picture of its benefits and risks.
Photo by rosario janza / Unsplash
Can a new drug help people with moderate to severe plaque psoriasis?
Plain Language Summary
What this means for you:
A new psoriasis drug completed a major trial, but the detailed results are not yet available. What this means for you:
A new psoriasis drug completed a major trial, but the detailed results are not yet available. View Original Abstract ↓
Status: COMPLETED | Phase: PHASE3
Condition(s): Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Intervention(s): Bimekizumab (DRUG), Placebo (OTHER)
Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.
Primary Outcome(s): Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16; Percentage of Participants With an Investigator's Global Assessment (IGA) Response at Week 16
Enrollment: 435 (ACTUAL)
Lead Sponsor: UCB Biopharma SRL
Start: 2018-02-05 | Primary Completion: 2018-12-28
Results posted: 2022-03-04